Federal Register / Vol. 86, No. 166 / Tuesday, August 31, 2021 / Notices 48747 

5267 or Email your request, including 

your address to: marla.jacobson@

nih.gov. Formal requests for additional 

plans and instruments must be 

requested in writing. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on May 19, 2021, page 27093 

(Vol. 86 FR 27093) and allowed 60 days 

for public comment. No public 

comments were received. The National 

Cancer Institute (NCI), National 

Institutes of Health, may not conduct or 

sponsor, and the respondent is not 

required to respond to, an information 

collection that has been extended, 

revised, or implemented on or after 

October 1, 1995, unless it displays a 

currently valid OMB control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: Evaluation of 

Office of Acquisitions System (OASYS) 

and FFRDC Contract Administration 

System (FCAS) Vendor Portals National 

Cancer Institute (NCI), 0925–NEW, 

Expiration Date XX/XX/XXXX, NEW, 

National Cancer Institute (NCI), 

National Institutes of Health (NIH). 

Need and Use of Information 

Collection: The National Cancer 

Institute (NCI) Office of Acquisitions 

(OA), located within the Office of the 

Director (OD) in the Office of 

Management (OM) at the National 

Cancer Institute (NCI), awards and 

administers contracts and simplified 

acquisitions in support of the Institute’s 

mission to prevent, diagnose and treat 

cancer. During the acquisition process, 

the OA ensures that customer service is 

paramount, and communications are 

open and continuous. Currently 

requests and correspondence are sent to 

and received from vendors through 

email with the exception of the FFRDC 

Contractor who submits through the 

FCAS Vendor Portal which is in 

production. To streamline processes, 

increase transparency and gain 

efficiencies, the OA developed OASYS 

and FCAS vendor portals to replace 

processes that are handled through 

email (future OASYS Vendor Portal 

Users) and were (current FCAS Vendor 

Portal Users) to individual OA 

recipients. The FCAS Vendor Portal and 

in the future, the OASYS Vendor Portal 

will serve as a one-stop shop for 

transmission of requests, reports, 

deliverables and other correspondence 

due on numerous research and 

development, in support of R&D 

contracts as well as those contract 

vehicles awarded using various Federal 

Acquisition Procedures including but 

not limited to FAR Part 8, Required 

Sources of Supplies and Services, FAR 

Part 13, Simplified Acquisition 

Procedures, and FAR Part 12, 

Acquisition of Commercial Items. These 

reports and deliverables cover a wide 

variety of topics in the areas of cancer 

research including prevention, 

detection, diagnosis, and control. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

232. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hours 

Survey—OASYS ............................... Individuals ........................................ 10 1 6/60 1 

Survey—FCAS .................................. Individuals ........................................ 1 1 6/60 1 

Registration—OASYS ....................... Corporations ..................................... 400 1 6/60 40 

Registration—FCAS .......................... Corporations ..................................... 1 1 6/60 1 

Data Field Information—OASYS ...... Individuals ........................................ 400 18 1/60 120 

Data Field Information—FCAS ......... Individuals ........................................ 61 63 1/60 64 

Add/Edit new Vendor User—OASYS Corporations ..................................... 40 1 6/60 4 

Add/Edit new Vendor User—FCAS .. Corporations ..................................... 6 1 6/60 1 

Totals ......................................... ........................................................... 919 11,501 ........................ 232 

Dated: August 26, 2021. 

Vivian Horovitch-Kelley, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2021–18767 Filed 8–30–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the National Heart, Lung, 

and Blood Advisory Council, August 31, 

2021–September 1, 2021, National 

Institutes of Health, Bethesda, 

Maryland, 20892, which was published 

in the Federal Register on August 4, 

2021, FR Doc 2021–16549, 86 FR 41983. 

This notice is being amended to 

change the start time for the second 

Open session on September 1, 2021, 

which will now be 12:30 p.m. and will 

still end at 2:30 p.m. as listed. The 

meeting is closed to the public. 

Dated: August 25, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18725 Filed 8–30–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Human Genome Research. 

The meeting will be open to the 

public as indicated below, the 94th 

meeting of the National Advisory 

Council for Human Genome Research 

open session will be livestreamed and 

available for viewing to the public from 

https://www.genome.gov/eventcalendar/94th-Meeting-of-NationalAdvisory-Council-for-Human-GenomeVerDate Sep<11>2014 20:08 Aug 30, 2021 Jkt 253001 PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 E:\FR\FM\31AUN1.SGM 31AUN1

khammond on DSKJM1Z7X2PROD with NOTICES
48748 Federal Register / Vol. 86, No. 166 / Tuesday, August 31, 2021 / Notices 

Research. The open session will be on 

September 13th and the start time will 

be 10:00 a.m. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Human Genome Research. 

Date: September 13–14, 2021. 

Open: September 13, 2021, 10:00 a.m. to 

3:00 p.m. 

Agenda: Report from Institute Director and 

Program Staff. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Closed: September 13, 2021, 3:00 p.m. to 

6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Closed: September 14, 2021, 8:30 a.m. to 

5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rudy O. Pozzatti, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, 5635 Fishers Lane, Suite 4076, MSC 

9306, Rockville, MD 20852, (301) 402–0838, 

pozzattr@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.genome.gov/council, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: August 25, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18726 Filed 8–30–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Bioengineering, Cellular and Circuit 

Neuroscience. 

Date: October 1, 2021. 

Time: 9:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Jyothi Arikkath, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5215, 

Bethesda, MD 20892, (301) 435–1042, 

arikkathj2@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

21–020: Cutting Edge Informatics Tools for 

Illuminating the Druggable Genome (U01). 

Date: October 5, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Noffisat Oki, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (240) 627–3648, 

noffisat.oki@nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Neuroscience of 

Basic Visual Processes Study Section. 

Date: October 6–7, 2021. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Kirk Thompson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1242, kgt@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 25, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18728 Filed 8–30–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–6280–D–01] 

Redelegation of Authority for the 

Office of Field Policy and Management 

AGENCY: Office of Field Policy and 

Management, Housing and Urban 

Development (HUD). 

ACTION: Notice of redelegation of 

authority. 

SUMMARY: Through this notice, the 

Assistant Deputy Secretary for Field 

Policy and Management and the 

Director for Field Policy and 

Management redelegate certain 

operational management authority to 

the HUD Regional Administrators 

located in Region I (Boston, MA); 

Region II (New York, NY); Region III 

(Philadelphia, PA); Region IV (Atlanta, 

GA); Region V (Chicago, IL); Region VI 

(Fort Worth, TX); Region VII (Kansas 

City, KS); Region VIII (Denver, CO); 

Region IX (San Francisco, CA); and 

Region X (Seattle, WA). 

DATES: Applicable Date: August 25, 

2021. 

FOR FURTHER INFORMATION CONTACT: John 

B. Shumway, Assistant General 

Counsel, Administrative Law Division, 

Department of Housing and Urban 

Development, at 451 7th Street SW, 

Room 9262; Washington, DC 20410– 

0500 or telephone number 202–402– 

5190 (this is not a toll-free number). 

Persons with hearing or speech 

impairments may access this number 

through TTY by calling the Federal 

Relay Service at 800–877–8339 (this is 

a toll-free number). 

SUPPLEMENTARY INFORMATION: In October 

2020, the Secretary of HUD delegated to 

the Assistant Deputy Secretary for Field 

Policy and Management and the 

Director for Field Policy and 

Management authority for the 

management and oversight of the 

Department’s field operations, which 

was published in the Federal Register at 


khammond on DSKJM1Z7X2PROD with NOTICES